HR Execs on the Move

Dallas Retirement Village

www.dallasretirementvillage.com

 
Dallas Retirement Village is a Dallas, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Northern Light Health

Northern Light Health exists to make healthcare work for you. That is our mission. That is our purpose. Northern Light Health is the most expansive integrated health care system in Maine. We provide care to people from Portland to Presque Isle and from Blue Hill to Greenville. We are comprised of nine member hospitals with 584 long-term beds, a single physician-led medical group, eight nursing homes, five emergency transport members, 37 primary care locations, and we employ more than 12,000 people in Maine.

Hoosier Oncology Group

Hoosier Oncology Group is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Occupational Environmental Health Solutions

Occupational Environmental Health Solutions is a Chatham, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AQ Safety

AQ Safety is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.